SGLT2 Inhibitors in Cardiovascular Diseases
Mechanisms, Clinical Impact, and Future Directions
Will be published approx. on 1. January 2027
Book
Paperback/Softback
200 pages
978-0-443-45382-3 (ISBN)
Description
SGLT2 Inhibitors in Cardiovascular Diseases: Mechanisms, Clinical Impact, and Future Directions reviews the impact of SGLT2 inhibitors on cardiovascular health in individuals with type 2 diabetes, chronic kidney disease, heart failure, and atherosclerosis. It synthesizes preclinical and clinical evidence to highlight the cardiovascular benefits of these drugs, initially developed for hyperglycemia management. The book details recent studies on SGLT2 inhibitors' effects on cognitive dysfunction, sudden death, ventricular arrhythmias, heart remodeling, and cancer risks in diabetic patients. It compares SGLT2 inhibitors with DPP4 inhibitors, emphasizing the efficacy of empagliflozin and dapagliflozin in reducing syncope and cardiovascular mortality, supported by trials like EMPA-REG OUTCOME and DECLARE-TIMI 58. Addressing a gap in literature, the book provides a comprehensive overview of SGLT2 inhibitors' cardiovascular benefits in high-risk populations, including atrial fibrillation and syncope. It offers valuable insights and recommendations for clinicians, researchers, and policymakers managing cardiovascular risk.
More details
Language
English
Place of publication
San Diego
United States
Publishing group
Elsevier Science Publishing Co Inc
Target group
Professional and scholarly
Product notice
Paperback (trade)
Unsewn / adhesive bound
Dimensions
Height: 235 mm
Width: 191 mm
Weight
449 gr
ISBN-13
978-0-443-45382-3 (9780443453823)
Copyright in bibliographic data is held by Nielsen Book Services Limited or its licensors: all rights reserved.
Schweitzer Classification
Person
Tong Liu, MD, PhD, FESC, FHRS, ISNE-F, Youth Committee member of ISE, is a Professor of Cardiology at Tianjin Medical University and Deputy Director of the Tianjin Institute of Cardiology. With over 200 publications, he specializes in cardiac remodeling, arrhythmic disorders, and cardiovascular aging, and is on the Stanford Top 2% Scientists list. Dr. Liu leads research on biomarkers of cardiovascular aging and developing novel cardiac age models. He serves on the editorial boards of leading journals such as Pacing and Clinical Electrophysiology and BMC Cardiovascular Disorders and is Editor-in-Chief of Current Cardiology Reviews. His work focuses on molecular biology, clinical research, and the potential role of SGLT-2 inhibitors in cardiovascular disease. Dr. Liu has also authored and edited nine books, including AI Augmented ECG Technology from Springer. His extensive research and leadership make him a prominent figure in cardiovascular aging and translational cardiology.
Content
Section I. Introduction and Overview
1. Overview of SGLT2 Inhibitors and Cardiovascular Disease
2. The Development of SGLT2 Inhibitors and Their Expanding Role in Cardiovascular Disease
Section II. Mechanisms of SGLT2 Inhibition in Cardiovascular Disease
3. Molecular Mechanisms of SGLT2 Inhibition in Cardiovascular Systems
4. SGLT2 Inhibition and Cardiovascular Pathophysiology
5. Impact of SGLT2 Inhibition on Cardiovascular Remodeling
Section III. Clinical Evidence and Applications
6. Cardiovascular Benefits of SGLT2 Inhibitors in Type 2 Diabetes
7. SGLT2 Inhibitors in Heart Failure
8. SGLT2 Inhibitors in Lipid Metabolism Disease. Focus on Atherosclerotic Cardiovascular
9. SGLT2 Inhibitors in Arrhythmias. Special Focus on Atrial Fibrillation and Syncope
10. SGLT2 Inhibitors vs. DPP4 Inhibitors in Cardiovascular Disease
11. SGLT2 Inhibitors in Cardiorenal and Metabolic Protection
Section IV. Efficacy and Safety of SGLT2 in Cardiovascular Diseases
12. Common Adverse Effects and Long-Term Safety
13. Efficacy and Safety in Special Populations
Section V. Future Directions and Unanswered Questions
14. Future Perspectives on SGLT2 Inhibitors in Cardiovascular Disease
15. Unanswered Questions and Ongoing Clinical Trials
1. Overview of SGLT2 Inhibitors and Cardiovascular Disease
2. The Development of SGLT2 Inhibitors and Their Expanding Role in Cardiovascular Disease
Section II. Mechanisms of SGLT2 Inhibition in Cardiovascular Disease
3. Molecular Mechanisms of SGLT2 Inhibition in Cardiovascular Systems
4. SGLT2 Inhibition and Cardiovascular Pathophysiology
5. Impact of SGLT2 Inhibition on Cardiovascular Remodeling
Section III. Clinical Evidence and Applications
6. Cardiovascular Benefits of SGLT2 Inhibitors in Type 2 Diabetes
7. SGLT2 Inhibitors in Heart Failure
8. SGLT2 Inhibitors in Lipid Metabolism Disease. Focus on Atherosclerotic Cardiovascular
9. SGLT2 Inhibitors in Arrhythmias. Special Focus on Atrial Fibrillation and Syncope
10. SGLT2 Inhibitors vs. DPP4 Inhibitors in Cardiovascular Disease
11. SGLT2 Inhibitors in Cardiorenal and Metabolic Protection
Section IV. Efficacy and Safety of SGLT2 in Cardiovascular Diseases
12. Common Adverse Effects and Long-Term Safety
13. Efficacy and Safety in Special Populations
Section V. Future Directions and Unanswered Questions
14. Future Perspectives on SGLT2 Inhibitors in Cardiovascular Disease
15. Unanswered Questions and Ongoing Clinical Trials